Biomarin Pharmaceutical Inc.

Cytec Technology Corporation

Other

Medivation Technologies, Inc.

Nokia Corporation

Edison Pharmaceuticals, Inc.

Siemens Medical Solutions Usa, Inc.

Brocade Communications Systems, Inc.

Amo Development, LLC

Monsanto Technology LLC

Eli Lilly and Company

Johnson & Johnson Consumer Companies, Inc.

Foundry Networks, Inc.

Rhodia Limited

J&j Consumer Companies, Inc.

Bing Wang

Daniel T Chu

Wei Zhang

Jian Chen

Yi Li

Jiangao Song

Guy M Miller

Sekhar S Boddupalli

Sathanjheri A Ravishankar

Alan S Rothenberg

Donald R James

David B Cheung

Devarayasamudram Ramachandran Nagaraj

Tarun Bhambhani

Kai Chen

Joseph C Walsh

Gang Chen

Alexander James Bridges

Hartmuth C Kolb

Umesh B Gangadharmath

Dhanalakshmi Kasi

Vani P Mocharla

Xianfeng Li

Farhad Karimi

Qianwa Liang

Tieming Zhao

Henry Clifton Padgett

Peter J H Scott

Satyanarayana Janagani

Jian Feng Chen

Jonathan L Sessler

Yong-Kang Zhang

Hong Fu

Mani Kancherla

Khalid Mahmood

Gail Walkinshaw

Shien-Tai Pan

Hoai Le

Victor Kai-Chieh Liang

Maurice Chow

Richard Thai

Yongbo Liu

Lesley A Brown

Ughetta Del Balzo

Leonard Edwin Post

Peter Riccio

Carmina Quintanar

Ying Feng

Yuqiao Shen

Brian A Duclos

Zhiyong Gao

Thomas Lee Collier

Harsha Kolla

Chunfang Xia

Quan Jiang

Lei Lu

Xianming Jin

Shichun Peng

Qi Chao

Robert G Heitel

Sridhar J Devarapalli

Qiang Cong

John Michael Tamkin

Shiming Wo

Daniel T W Chu

Stephen F Flaim

Deepak Bansal

Hon M Lee

Peter-Patrick De Guzman

Sam Htin Moy

Dwight Shamblee

Sylvain Gilat

Mikhail Levin

Xiangfeng Li

Steven Bobzin

Arkadij M Elizarov

Avinash Jindal

Wyeth B Callaway

Victor Kardos

Santhanjheri A Ravishankar

Josanlet C Villegas

Sekhar Bodupalli

Sekhar Boddupalli

Victor J Kardos

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Glycolate oxidase inhibitors for the treatment of disease

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R, R, R, Rand Rare as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors

A system and method for performing ophthalmic surgery using an ultra-short pulsed laser is provided. The system includes a laser engine configured to provide an ultra-short pulsed laser beam, optics configured to direct the laser beam to an undocked eye of a patient, an eye tracker configured to measure five degrees of freedom of movement of the undocked eye, an optical coherence tomography module configured to measure depth of the undocked eye, and a controller configured to control laser beam position on the undocked eye toward a desired laser pattern based on depth and the five degrees of freedom of movement of the undocked eye. Adaptive optics are also provided. Also disclosed are a scleral ring including fiducial markings and a compliant contact lens and fluid tillable contact lens configured to facilitate ultra-short pulsed laser surgery while reducing or eliminating eye docking requirements.

System and method for ophthalmic laser surgery employing eye tracking without eye docking

Glucosylceramide synthase inhibitors for the treatment of diseases

A laser surgery system includes: a gantry configured to be attached to a structural frame; a docking receptacle configured to be removably attached to an eye docking assembly which is attached to an eye; an adjustable table attached to the gantry; a lens assembly attached to the adjustable table, wherein the adjustable table is configured to move the lens assembly relative to the eye; one or more connectors configured to attach the docking receptacle to the gantry, at least one of the connectors being configured to dynamically adjust the distance between a surface of the gantry and a surface of the docking receptacle; and a controller configured to maintain a target distance between the lens assembly and a reference area of the eye docking assembly.

Eye docking for laser eye surgery

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R, R, R, Rand Rare as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.

Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency

An electrostatic modification reagent and a process for beneficiating a mineral substrate by electrostatic separation as described herein. The electrostatic modification reagent may be used in an electric separation process for separating components from a mineral ore or sand.

Electrostatic modification reagent and process for enhancing electrostatic separation in the beneficiation of ores

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS). 

Provided herein are (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt forms, including crystalline forms, and methods of their preparation. Pharmaceutical compositions comprising a (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt are also provided, as are methods of using (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt to treat a disease or condition, such as a cancer.

Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt

Growing community of inventors

San Jose, CA, United States of America

Bing Wang